Last reviewed · How we verify
Muphoran (FOTEMUSTINE)
Fotemustine works by cross-linking DNA, thereby inhibiting DNA replication and transcription.
Muphoran (Fotemustine) is a small molecule chemotherapeutic agent developed by Ipsen, currently owned by Ipsen. It is used to treat hairy cell leukemia. The exact target of Fotemustine is unknown, but it is classified as a nitrosourea compound. It has a short half-life of 0.38 hours. Fotemustine is patented and its commercial status is not off-patent.
At a glance
| Generic name | FOTEMUSTINE |
|---|---|
| Drug class | fotemustine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Mechanism of action
Imagine your DNA as a long, twisted ladder. Fotemustine is like a chemical that goes in and links the rungs of the ladder together, making it hard for the cell to make copies of itself and function properly. This ultimately leads to cell death.
Approved indications
Common side effects
- Tonsillar haemorrhage
- Acute myeloid leukaemia
- Mucosal inflammation
Key clinical trials
- Fotemustine in Treating Patients With Metastatic Melanoma (PHASE2)
- A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) (PHASE3)
- Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma (PHASE3)
- A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver (PHASE3)
- A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma (PHASE1,PHASE2)
- Treatment of Primary CNS Lymphoma ( FTD ) (PHASE2)
- Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma (PHASE4)
- A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |